Second Circuit revives Tylenol autism, ADHD lawsuits against Kenvue

Kenvue, Inc.

Kenvue, Inc.

KVUE

0.00
  • Kenvue faces federal acetaminophen product-liability litigation alleging prenatal use is linked to autism or ADHD.
  • The Second Circuit issued a procedural ruling on expert admissibility, not on general causation between acetaminophen and ASD or ADHD.
  • The appeals court upheld exclusion of two plaintiff experts, reinstated three others, vacated the district court judgments, remanded for further review.
  • The district court will revisit the cases under the appellate opinion, with timing set by the district court.
  • Kenvue disputes any causal link, plans to keep challenging plaintiff experts, continues to defend the cases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kenvue Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.